2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS

      abstract
      1,* , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 4 , 4 , 28 , 28 , 29 , 30 , 27 , 31 , 32 , 33 , 30 , 34 , 35 , 36 , 37 , 38 , 39 , 10 , 28 , 40 , 41 , 33 , 42 , 43 , 5 , 44 , 45 , 46 , 40 , 41 , 38 , 47 , 4
      HemaSphere
      Lippincott Williams & Wilkins

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). Aims: The present study is a 3-years follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. Methods: This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. Results: After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with ISS stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. Summary/Conclusion: In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups.

          Related collections

          Author and article information

          Journal
          Hemasphere
          Hemasphere
          HS9
          HemaSphere
          Lippincott Williams & Wilkins (Philadelphia, PA )
          2572-9241
          23 June 2022
          June 2022
          : 6
          : Suppl
          : 1856-1857
          Affiliations
          [1 ]Azienda Ospedaliera of Cosenza, Cosenza
          [2 ]Businco Hospital, Cagliari
          [3 ]Azienda Socio-Sanitaria Territoriale-Papa Giovanni XXIII, Bergamo
          [4 ]Azienda Ospedaliera di Cosenza, COSENZA
          [5 ]Ospedale Cardarelli, Napoli
          [6 ]University of Catania, Catania
          [7 ]Ospedale Umberto I, Nocera Inferiore
          [8 ]Parma University Hospital, Parma
          [9 ]IRCCS Fondazione Policlinico San Matteo, Pavia
          [10 ]AORN “Sant’Anna e San Sebastiano”, Caserta
          [11 ]Azienda Ospedaliera Santa Maria of Terni, Terni
          [12 ]Ospedale S. Croce, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio of Fano, Fano
          [13 ]Università Cattolica, Fondazione Policlinico Gemelli IRCCS, Rome
          [14 ]Careggi Hospital, Firenze
          [15 ]University of Bari “Aldo Moro” Medical School, Internal Medicine “G. Baccelli”, Policlinico, Bari
          [16 ]Padua University School of Medicine, Padova
          [17 ]Hematology Unit, Lecce
          [18 ]Hematology Unit, Brindisi
          [19 ]Istituto Nazionale Tumori, Fondazione ‘G. Pascale’, IRCCS, Napoli
          [20 ]IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture
          [21 ]Hospital University Riuniti, Foggia
          [22 ]IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo
          [23 ]IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
          [24 ]A.O. Spedali Civili, Brescia
          [25 ]AO S.G. Moscati, Aversa
          [26 ]G. Garibaldi Hospital, Catania
          [27 ]AOUC Policlinico, Bari
          [28 ]University “Magna Graecia” of Catanzaro, Catanzaro
          [29 ]Internal Medicine and Medical Specialties, University of Palermo, Palermo
          [30 ]Great Metropolitan Hospital “Bianchi-Melacrino-Morelli”, Reggio Calabria
          [31 ]University of Verona, Verona
          [32 ]S. Eugenio Hospital, Roma
          [33 ]DISM, University of Udine, Udine
          [34 ]Ospedale Santa Maria della Misericordia, University of Perugia, Perugia
          [35 ]Fabrizio Spaziani Hospital, Frosinone
          [36 ]S. Maria di Loreto Nuovo Hospital, Napoli
          [37 ]AUSL-IRCCS, Reggio Emilia
          [38 ]Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano
          [39 ]National Research Institute of Biomedicine and Molecular Immunology, Reggio Calabria
          [40 ]University of Torino, AOU Città della Salute e della Scienza di Torino, Torino
          [41 ]Seràgnoli Institute of Hematology and Medical Oncology, University of Bologna, Bologna
          [42 ]Università Cattolica, Fondazione Policlinico Gemelli IRCCS, Roma
          [43 ]Hematology Section, University of Catania, Catania
          [44 ]Sapienza University of Rome, Roma
          [45 ]AOU Ospedali Riuniti di Ancona, Ancona
          [46 ]”Aldo Moro” University School of Medicine, Bari
          [47 ]Biotechnology Research Unit, AO di Cosenza, Cosenza, Italy
          Article
          01856
          10.1097/01.HS9.0000850772.23648.13
          9429134
          d8460e8e-498b-495b-aa0b-deb16ce27fd8
          Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

          This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

          History
          Categories
          Publication Only
          Custom metadata
          TRUE

          Comments

          Comment on this article